Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Celebrex approved in first market outside U.S.

Jan. 22, 1999

Snow Brand reports new developments concerning cevimeline

Jan. 22, 1999

Chugai presents new COX-2 inhibitor series

Jan. 22, 1999

Medarex and Centeon begin phase II study of MDX-33 as ITP treatment

Jan. 14, 1999

Medeva acquires license for scleroderma Rx from Connetics

Jan. 13, 1999

Priority review status granted for Merck & Co.'s COX-2 inhibitor

Jan. 13, 1999

Max Planck reports cysteine-containing compounds as MMP inhibitors

Jan. 12, 1999

Shionogi patents water-soluble inhibitors of human sPLA2

Jan. 12, 1999

Important end-of-year approval by FDA: Celebrex for arthritis

Jan. 4, 1999

New COX-2 inhibitor series patented by Searle

Jan. 4, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...